title: Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis.
abstract: BACKGROUND
  The growth of economic analyses and in particular cost-utility analyses (CUA), which use the QALY as a measure of outcome, has heightened the interest in the methodologies used to calculate the QALY. The EQ-5D has produced quite different utility values from that of the SF-6D. This article seeks to understand these differences using a cohort of patients with inflammatory arthritis.
  
  
  OBJECTIVE
  To examine the relationship between the disease-specific measure, Health Assessment Questionnaire (HAQ) disability index (DI) and the preference-based measures, SF-6D, EQ-5D and European League Against Arthritis (EULAR) Disease Activity Score (DAS) in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
  
  
  METHODS
  Patients with RA and PsA (n = 504) attending a tertiary rheumatology referral centre completed the HAQ, SF-6D and the EQ-5D before starting biological therapy and again 12 months later. The SF-36 was converted into a utility using the preference-based SF-6D. Clinical outcomes such as the DAS, joint counts and laboratory measures were also recorded. We calculated single index utility scores from the preference-based instruments using UK population norms. We used regression analysis to derive a mapping function and calculated utility scores from the HAQDI and the DAS 28.
  
  
  RESULTS
  The mean utility observed at baseline for RA was 0.43 for the EQ-5D and 0.54 for the SF-6D and for PsA was 0.49 for the EQ-5D and 0.57 for the SF-6D. The utility gain demonstrated by the EQ-5D was over twice that of the SF-6D. The EQ-5D scored 17% of the RA group as less than 0 (state defined as worse than death); 7% of this group remained less than 0 at follow-up. The distribution of the utility estimates was similar for both RA and PsA.
  
  
  CONCLUSIONS
  Our findings draw attention to the impact of states worse than death on the overall distribution for the EQ-5D derived utilities and how these impact on its use in practice. EQ-5D-derived QALY changes are over twice that of the SF-6D. The implication of this for decision makers is that cost-effectiveness evaluations for treatments in this disease class are likely to be very sensitive to the choice of utility measure.
authors.affiliation: National Centre for Pharmacoeconomics, St. James' Hospital, Dublin 8, Ireland. radams@stjames.ie
authors.forename: Roisin
authors.initials: R
authors.lastname: Adams
authors.forename: Cathal
authors.initials: C
authors.lastname: Walsh
authors.forename: Douglas
authors.initials: D
authors.lastname: Veale
authors.forename: Barry
authors.initials: B
authors.lastname: Bresnihan
authors.forename: Oliver
authors.initials: O
authors.lastname: FitzGerald
authors.forename: Michael
authors.initials: M
authors.lastname: Barry
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015535:Arthritis, Psoriatic / Q000191:economics*; D001172:Arthritis, Rheumatoid / Q000191:economics*; D003362:Cost-Benefit Analysis / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017059:Models, Econometric; D017063:Outcome Assessment, Health Care / Q000379:methods*; D019057:Quality-Adjusted Life Years; D012720:Severity of Illness Index
references.citation: Rheumatology (Oxford). 2004 Jan;43(1):62-72
references.pmid: 12890861
references.citation: Ann Rheum Dis. 2010 Jan;69(1):222-5
references.pmid: 19293160
references.citation: Arthritis Rheum. 1980 Feb;23(2):137-45
references.pmid: 7362664
references.citation: Rheumatology (Oxford). 2006 Aug;45(8):1029-38
references.pmid: 16782734
references.citation: Health Econ. 2006 Nov;15(11):1229-36
references.pmid: 16625671
references.citation: Pharmacoeconomics. 2008;26(9):781-98
references.pmid: 18767898
references.citation: J Rheumatol. 1982 Sep-Oct;9(5):789-93
references.pmid: 7175852
references.citation: Med Care. 2004 Nov;42(11):1125-31
references.pmid: 15586840
references.citation: Appl Health Econ Health Policy. 2004;3(2):91-102
references.pmid: 15702946
references.citation: Rheumatology (Oxford). 2005 Sep;44(9):1169-75
references.pmid: 15956093
references.citation: Health Econ. 1996 Mar-Apr;5(2):141-54
references.pmid: 8733106
references.citation: Soc Sci Med. 2007 Mar;64(6):1242-52
references.pmid: 17157971
references.citation: Pharmacoeconomics. 2008;26(2):121-9
references.pmid: 18198932
references.citation: Mod Rheumatol. 2006;16(2):77-84
references.pmid: 16633926
references.citation: Health Qual Life Outcomes. 2008 Jul 14;6:51
references.pmid: 18625052
references.citation: Br J Rheumatol. 1996 Sep;35 Suppl 2:4-7
references.pmid: 8810683
references.citation: Arthritis Rheum. 1995 Oct;38(10):1351-62
references.pmid: 7575685
references.citation: Br J Rheumatol. 1997 May;36(5):551-9
references.pmid: 9189057
references.citation: Arthritis Rheum. 2001 Apr;45(2):151-8
references.pmid: 11324779
references.citation: Value Health. 2009 Sep;12(6):1026-34
references.pmid: 19473335
references.citation: Br J Rheumatol. 1994 Jul;33(7):655-62
references.pmid: 8019795
references.citation: Int J Technol Assess Health Care. 2009 Apr;25(2):181-9
references.pmid: 19331709
references.citation: Curr Med Res Opin. 2008 Sep;24(9):2639-50
references.pmid: 18687164
references.citation: Arthritis Rheum. 1996 Jan;39(1):34-40
references.pmid: 8546736
references.citation: Eur J Health Econ. 2005 Sep;6(3):253-60
references.pmid: 15968563
references.citation: Arthritis Rheum. 1999 Feb;42(2):347-56
references.pmid: 10025930
references.citation: Med Care. 1992 Jun;30(6):473-83
references.pmid: 1593914
references.citation: Health Technol Assess. 2004 Mar;8(11):iii, 1-91
references.pmid: 14982655
references.citation: Med Care. 2003 Jul;41(7):791-801
references.pmid: 12835603
references.citation: Ann Rheum Dis. 2005 Jul;64(7):995-1002
references.pmid: 15550533
references.citation: J Health Econ. 2002 Mar;21(2):271-92
references.pmid: 11939242
references.citation: Popul Health Metr. 2009 Jan 13;7:3
references.pmid: 19144115
references.citation: Qual Life Res. 2009 Nov;18(9):1195-205
references.pmid: 19777373
references.citation: Qual Life Res. 2005 Jun;14(5):1333-44
references.pmid: 16047508
references.citation: Rheumatology (Oxford). 2007 Aug;46(8):1345-54
references.pmid: 17562686
references.citation: Health Econ. 2010 Jun;19(6):683-96
references.pmid: 19504545
references.citation: Arthritis Rheum. 2007 Aug 15;57(6):963-71
references.pmid: 17665482
references.citation: Pharmacoeconomics. 1995 Sep;8(3):245-52
references.pmid: 10155620